Top Markets
#1 DogBull DogBull +36.53%
#2 Siacoin Siacoin +30.77%
#3 The Bitcoin Bull The Bitcoin Bull +30.72%
#4 Merlin's Seal BTC Merlin's Seal BTC +25.80%
#5 Cash Cat Cash Cat +20.41%
#6 Pons Pons +19.16%
#7 MarsCoin MarsCoin +17.74%
#8 Ontology Gas Ontology Gas +14.56%
#9 Akedo Akedo +12.07%
#10 Uniswap Uniswap +10.77%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Yantai Zhenghai Biotechnology Co., Ltd. Yantai Zhenghai Biotechnology Co., Ltd.

Yantai Zhenghai Biotechnology Co., Ltd.

300653
Rank in Stocks #14774
Yantai Zhenghai Biotechnology Co., Ltd., founded in 2003 and based in Yantai,... Yantai Zhenghai Biotechnology Co., Ltd., founded in 2003 and based in Yantai, China, specializes in the innovation, manufacturing, and commercialization of regenerative medical materials across China. The company's product offerings include a bone repair material, which is a partially deproteinized substance derived from calf cancellous bone after undergoing a series of processes like decellularization and degreasing. It also provides membranes for oral cavity repair, specifically designed to address shallow soft tissue defects in the mouth. Under the "Heal-All" brand, it supplies biomembranes used in neurosurgical procedures to mend defects of the cerebral dura mater. Additionally, the "Heal-Full" brand encompasses skin repair membranes developed for treating wounds within the dermal layer.
Share Price
$2.21
Market Cap
$393.35M
Change (1 day)
1.87%
Change (1 year)
-25.17%
Country
CN
Trade Yantai Zhenghai Biotechnology Co., Ltd. (300653)

Category

Healthcare
Revenue for Yantai Zhenghai Biotechnology Co., Ltd. (300653)
Revenue in Sep 2026 TTM: 0
According to Yantai Zhenghai Biotechnology Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Yantai Zhenghai Biotechnology Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH